What is the appropriate workup and first‑line treatment for an older adult with suspected Alzheimer’s disease presenting with progressive memory loss and cognitive decline?

Workup and First-Line Treatment for Alzheimer's Disease

For an older adult with suspected Alzheimer's disease, initiate a comprehensive cognitive and neurologic assessment in primary care, followed by acetylcholinesterase inhibitor therapy (donepezil, rivastigmine, or galantamine) as first-line treatment for mild-to-moderate disease. 12

Diagnostic Workup Algorithm

Initial Primary Care Assessment

The diagnostic evaluation should include 1:

• Standardized cognitive testing using validated instruments (e.g., MMSE, MoCA) to establish baseline cognitive function

• Comprehensive history focusing on:

  • Timeline and pattern of memory loss (gradual vs. rapid onset)
  • Impact on activities of daily living
  • Behavioral and neuropsychiatric symptoms
  • Vascular risk factors (hypertension, diabetes, stroke history)
  • Medication review for anticholinergic effects

• Collateral information from family members or care partners is critical, as patients may lack insight into their deficits 1

• Neurologic examination assessing for:

  • Focal motor or sensory deficits
  • Extrapyramidal signs
  • Language or social-behavioral abnormalities

Red Flags Requiring Urgent Specialist Referral

Immediately refer to a dementia specialist if 13:

• Rapid cognitive decline: MMSE loss ≥3-4 points within 6-12 months
• Early-onset dementia: Age <65 years at symptom onset
• Atypical presentations: Prominent language dysfunction, behavioral changes, or motor symptoms
• Delirium features: Fluctuating attention or acute confusion requiring urgent evaluation

These presentations have substantially different differential diagnoses and may represent treatable conditions requiring expedited workup.

First-Line Pharmacologic Treatment

Mild-to-Moderate Alzheimer's Disease

Acetylcholinesterase inhibitors are the standard first-line therapy 24:

• Donepezil, rivastigmine, or galantamine - all three are equally endorsed
• These medications provide mild improvements in cognition, behavior, and activities of daily living
• Optimize to therapeutic doses for each individual patient 3

Important consideration: Rivastigmine may offer additional benefit in patients with rapid cognitive decline or significant vascular risk factors 3

Common adverse effects to counsel patients about 5:

• Nausea, vomiting, diarrhea (most common)
• Dizziness and confusion
• Cardiac arrhythmias (monitor in patients with cardiac disease)

Moderate-to-Severe Alzheimer's Disease

Add memantine (N-methyl-D-aspartate receptor antagonist) 24:

• Can be used as monotherapy for moderate disease or in combination with acetylcholinesterase inhibitors
• Generally well-tolerated with fewer gastrointestinal side effects than cholinesterase inhibitors
• Evidence for combination therapy is rational and safe, though clinical benefit magnitude remains debated 3

Severe Alzheimer's Disease

Memantine monotherapy is appropriate when acetylcholinesterase inhibitors are not tolerated 4

Critical Management Considerations

What NOT to Use

The following have no evidence of benefit and should not be prescribed 25:

• Ginkgo biloba
• Nonsteroidal anti-inflammatory drugs (NSAIDs)
• Omega-3 fatty acids
• Statins (for cognitive improvement)
• Estrogen therapy
• Vitamin E (does not improve cognition, though may have modest effect on functional decline)

Behavioral Symptoms

Brexpiprazole is FDA-approved specifically for agitation associated with Alzheimer's disease 2

Caution with atypical antipsychotics: While they may improve behavioral symptoms, they are associated with increased mortality in older patients with dementia 5

Monitoring and Follow-Up

• Assess cognitive and functional status every 6 months using standardized measures 4
• More frequent follow-up (every 3 months) is warranted for rapid decliners given accelerated loss of autonomy and increased caregiver burden 3
• Continue pharmacologic therapy until there are no meaningful social interactions and quality of life has irreversibly deteriorated 4

Special Populations Requiring Aggressive Vascular Risk Factor Control

Patients with rapid cognitive decline often have concurrent vascular pathology 3. In these patients:

• Aggressively manage hypertension, diabetes, and hyperlipidemia
• Consider brain imaging to identify white matter changes and lacunar infarctions
• These patients may respond better to rivastigmine than donepezil for activities of daily living 3

Common Pitfalls to Avoid

1. Delaying treatment initiation: Early diagnosis and treatment with cholinesterase inhibitors may stabilize or reduce the rate of decline 4

2. Missing delirium: Rule out superimposed delirium from infections, metabolic causes, or medications with anticholinergic effects before attributing all symptoms to dementia progression 3

3. Inadequate dosing: Ensure medications are titrated to optimal therapeutic doses rather than stopping at starting doses 3

4. Failing to recognize atypical presentations: These require specialist evaluation and may represent treatable conditions 1